Pirfenidone decreases exposure of nerandomilast and reduces efficacy at 9 mg twice daily dosage. Dosage should be maintained at 18 mg twice daily.
Source: NLP:nerandomilast
Brand names: Jascayd
Route: Oral
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data on JASCAYD use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. There are maternal and fetal risks associated with untreated idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) during pregnancy (Clinical Considerations). Based on findings from animal reproduction studies, JASCAYD may increase the risk for fetal loss. In an embryo-fetal development study in rats, oral administration of nerandomilast to pregnant rats during organogenesis at an exposure approximately 5 times the maximum recommended human dose (MRHD) of 36 mg/day resulted in an increase in embryo-fetal losses (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk of fetal loss. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and miscarriage in clinically recognized pregnancies is 15% to 20%. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Untreated IPF or PPF can lead to respiratory failure and mortality in the mother and intrauterine growth restriction, preterm birth, fetal hypoxia, and neonatal death. Data Animal Data In an embryo-fetal development study in pregnant rats dosed by the oral route during the period of organogenesis from gestation days 6 to 17, nerandomilast caused an increase in embryo-fetal losses (pre- and post-implantation loss and decreased mean number of live fetuses) at an exposure that was approximately 5 times the MRHD (on an AUC basis with a maternal oral dose of 6 mg/kg/day). Maternal toxicity, as evidenced by decreased body weight gains and adverse clinical signs, was observed at exposures approxima
3 interactions on record
Pirfenidone decreases exposure of nerandomilast and reduces efficacy at 9 mg twice daily dosage. Dosage should be maintained at 18 mg twice daily.
Source: NLP:nerandomilast
Moderate or strong CYP3A inducers decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD. Concomitant use should be avoided.
Source: NLP:nerandomilast
Strong CYP3A inhibitors increase exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions. Dosage reduction to 9 mg twice daily is recommended.
Source: NLP:nerandomilast